Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors
Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5760-5773
DOI: 10.1021/acs.jmedchem.4c03120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.03.2025. Verfasst von Chad R Schultz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, United States. Hauptthemen laut MEDLINE: Drug Design, Ornithine Decarboxylase Inhibitors, Ornithine Decarboxylase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Michigan State University.
Abstract (Originalsprache)
We here describe the design, synthesis, and biological activity of novel ornithine decarboxylase (ODC) inhibitors that show significantly higher potency in vitro than α-difluoromethylornithine (DFMO), a U.S. Food and Drug Administration (FDA) approved drug. We report two X-ray structures of ODC complexed with new ODC inhibitors, computational docking, molecular dynamics, and binding free energy calculations to validate the experimental models. The X-ray structures reveal that covalent adducts with pyridoxal phosphate (PLP) are formed in the active site of the human ODC enzyme, as verified by their preparation and enzymatic testing. Finally, we verified that the cellular activity of endogenous ODC was inhibited, and polyamine levels were reduced. Given that ODC is a clinically validated target, combined with the fact that DFMO is currently the only ODC inhibitor in clinical use for several indications, the further development of more potent ODC inhibitors with superior activity and physical properties is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, United States.
- International Center for Polyamine Disorders, Grand Rapids, Michigan 49503, United States.
- Department of Pharmacology and Toxicology, College of Human Medicine, East Lansing, Michigan 48824, United States.
- Department of Structural Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.
- Department of Chemistry, College of Natural Science, Michigan State University, East Lansing, Michigan 48824, United States.
ORCID-Profile: Karsten Melcher, Nuno M S Almeida, Angela K Wilson, André S Bachmann
Förderung
- NCI NIH HHS
- National Cancer Institute
- Michigan State University
- Argonne National Laboratory
Zitieren
APA
Schultz, C. R., Aleiwi, B., Zhou, X. E., Suino-Powell, K., Melcher, K., Almeida, N. M. S., Wilson, A. K., Ellsworth, E. L., & Bachmann, A. S. (2025). Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors. Journal of Medicinal Chemistry, 68(5), 5760-5773. https://doi.org/10.1021/acs.jmedchem.4c03120
Vancouver
Schultz CR, Aleiwi B, Zhou XE, Suino-Powell K, Melcher K, Almeida NMS, et al. Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors. Journal of Medicinal Chemistry. 2025;68(5):5760-5773. doi:10.1021/acs.jmedchem.4c03120
BibTeX
@article{Schultz2025,
author = {Schultz, Chad R and Aleiwi, Bilal and Zhou, X Edward and Suino-Powell, Kelly and Melcher, Karsten and Almeida, Nuno M S and Wilson, Angela K and Ellsworth, Edmund L and Bachmann, André S},
title = {Design, Synthesis, and Biological Activity of Novel Ornithine Decarboxylase (ODC) Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {5},
pages = {5760--5773},
doi = {10.1021/acs.jmedchem.4c03120}
}
EUVIMED